Navigation Links
Independent Clinical Study Finds Vemma is Highly Bioavailable Showing Increase in Vitamins and Antioxidants in the Blood*
Date:11/13/2009

This second published independent clinical study on Vemma, its physician formulated liquid supplement, has been published in the Journal of Agricultural and Food Chemistry (Volume 57, Number 19, October 14, 2009). The clinical study entitled, “Bioavailability and Antioxidant Effects of a Xanthone-Rich Mangosteen (Garcinia mangostana) Product in Humans” found that Vemma is highly bioavailable, showing an increase in vitamins and antioxidants in the blood.*

Scottsdale, AZ (PRWEB)November 13, 2009 -- Vemma Nutrition Company announced today that its second independent clinical study on Vemma, its physician formulated liquid supplement, has been published in the Journal of Agricultural and Food Chemistry (Volume 57, Number 19, October 14, 2009). The clinical study entitled, “Bioavailability and Antioxidant Effects of a Xanthone-Rich Mangosteen (Garcinia mangostana) Product in Humans” found that Vemma is highly bioavailable, showing an increase in vitamins and antioxidants in the blood.*

Clinical studies are not mandated for wellness companies, yet Vemma, being confident in putting its flagship nutritional formula to the test, chose to fund two, independent clinical studies. The Vemma formula contains the antioxidant-rich, whole fruit mangosteen pericarp (rind) with a combination of full spectrum vitamins, plant-sourced minerals, glyconutrient-rich aloe vera and organic green tea. Two ounces, once a day is the recommended dosage of Vemma to help people build a solid nutritional foundation. BK Boreyko, President and CEO of Vemma, commented, “To be published in both the Journal of Agricultural and Food Chemistry and The Journal of Medicinal Food sets Vemma apart from the competition with an impressive scientific portfolio. These results give validation to consumers and our Brand Partners that Vemma offers possible protective effects through its highly bioavailable and nutritious delivery system.*”

Dr. Boxin Ou from the independent Brunswick Laboratories led the double-blind, placebo-controlled clinical trial to determine the overall bioavailability (proportion which is absorbed and utilized by the body) and antioxidant effects of the Vemma formula in the human body. The trial took place over a 24 hour period of time and involved an equal number of generally healthy male and female subjects between 20 and 23 years of age. Subjects were randomly divided into two groups, the Vemma group and placebo group. Before the products were consumed, each participant’s blood was measured for baseline testing. Participants received either a single dose (2 ounces/59 mL) of the Vemma formula or the placebo before breakfast. Blood samples were then collected from each participant before and numerous times after taking the Vemma formula or placebo to track the presence of specific nutrients.

The noteworthy nutrients that showed up in the blood serum of the Vemma participants were vitamins B2, B5, ORAC (antioxidant levels) and alpha-mangostin, each reaching their maximum concentrations. ORAC materialized in the blood within one hour and maintained elevated saturation levels for six hours after intake. In the placebo group, no change in the blood serum was observed.

Yibing Wang M.D., Ph.D., Vemma Director of Product Development and Research, added, “It’s a great honor to have Vemma accepted for publication in a reputable journal such as the Journal of Agricultural and Food Chemistry. The trial results indicate Vemma delivers healthful nutrition in a highly bioavailable liquid form.*”

Vemma’s first clinical study entitled, “Effect of a Mangosteen Dietary Supplement on Human Immune Function: A Randomized, Double-Blind, Placebo-Controlled Trial” can also be viewed in The Journal of Medicinal Food (Volume 12, Number 4, August, 2009). The Vemma formula is available in several product options including Vemma, Verve, a healthy energy drink, and Vemma NEXT™, a premium liquid children’s formula. Vemma branded products are distributed worldwide through a hybrid network of independent Brand Partners and select retail locations.

To preview the study please visit http://pubs.acs.org/doi/abs/10.1021/jf901012f

To learn more about the health benefits of Vemma products and to become a Vemma Brand Partner, visit www.vemma.com.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

For media inquiries, please contact: Danielle DiOrio | DiOrio PR | (610) 945-8747

# # #

Read the full story at http://www.prweb.com/releases/clinical_study/vemma/prweb3197144.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Guardian Recognized for Service, Products and Reputation by Independent Research Group
2. Baptist Medical Center's Patient Outcomes Among Highest in the Nation, According to Independent Study
3. Independent Study: OxiTitan VLR Antimicrobial Coating Kills Virus on Surfaces
4. Connectyx Technologies Retained the Marcum Group in New York as its Independent Registered Public Accountant for the Purpose of Becoming a Fully Reporting Company
5. RCRC Independent Review Board Announces DHHS Research Oversight
6. URAC Open Public Comment Period for New Independent Review Organization Standards
7. GSK Limits Medical Education Funding to Independent Programs With Highest Impact on Patient Care
8. Gentiva(R) Health Services Announces Appointment of Three Independent Directors
9. 2 Independent Studies Released on the Effectiveness of Prostate Cancer Treatment
10. Independent Analysis Shows Granite Countertops Pose No Health Risk
11. BioNeutrals Ygiene(TM) Achieves Worlds Fastest Kill Time With a 100% Total Spore Eradication Verified In Independent Sporicidal/Sterilant Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... 26, 2016 , ... Catalent Pharma Solutions, the leading global ... and global clinical supply services, today announced two key appointments and the opening ... and strategic growth plans in the Asia Pacific region. , Howard Kim has ...
(Date:5/26/2016)... CA (PRWEB) , ... May 26, 2016 , ... In an effort to provide hair ... available to both Snapchat users and those who do not use the app. Dr. Mohebi, ... his new page, Dr. Mohebi Live . , Dr. Mohebi says, “The positive ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... for eating disorders, is opening a brand new child and adolescent residential treatment ... and their families with even more specialized eating disorder treatment and access to ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... multitude of activities from daily practices, arts & crafts, discussions, and games all ... East-D’Anna and Christy Evans have combined backgrounds in kids’ yoga, collegiate sport yoga ...
(Date:5/26/2016)... ... May 26, 2016 , ... Eugene Batelli, ... Along with his wonderful accolades and stellar patient reviews, Dr. Batelli continues to ... , Dr. Eugene Batelli is a highly trained Podiatric Surgeon who specializes in ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... , May 25,2016 FDA ... near-infrared Cellvizio platform for urological and surgical applications ... MKEAY) inventor of Cellvizio®, the multidisciplinary confocal laser ... milestone in the US with the 12 th ... Drug Administration (FDA). This new FDA clearance covers ...
(Date:5/25/2016)... , Germany and GERMANTOWN, ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: ... licensing and co-development agreement with Therawis Diagnostics GmbH to develop ... be to develop and market PITX2 as a marker to ... high-risk breast cancer patients. "We are pleased to ...
(Date:5/25/2016)... According to market research "Global ... Demand Forecast to 2022 - Industry Insights by Type ... by P&S Market Research, the global insulin delivery device ... it is expected to grow at a CAGR of ... segment is expected to witness the fastest growth at ...
Breaking Medicine Technology: